Abstract
Our results suggested that anti-CFH autoantibodies could attenuate pristane-induced lupus nephritis by increasing bio-functions of CFH on regulating complement activation and controlling inflammation.
Introduction
Lupus nephritis (LN) is a severe complication of Systemic Lupus Erythematosus (SLE), characterized by immune-mediated kidney damage. A central player in this pathogenesis is the complement system. Complement Factor H (CFH) serves as a vital regulator, acting as a "brake" on the alternative pathway to prevent self-attack. While autoantibodies against CFH are typically associated with disease progression in conditions like atypical hemolytic uremic syndrome (aHUS), clinical observations in LN patients have suggested a paradoxical protective role. This study investigates the mechanism behind these "heroic" autoantibodies using a murine model.
Methods
The researchers employed a pristane-induced lupus model in Balb/c mice. Twenty-four mice were divided into groups, including a "Pristane-CFH" group immunized with human CFH (hCFH) to induce anti-CFH autoantibodies. Over six months, the team monitored renal function via proteinuria and serum creatinine. Kidney health was further assessed through Periodic Acid-Schiff (PAS) staining and immunofluorescence to detect immune deposits (IgG, C1q, C3) and inflammatory markers like IL-6.
Results and Discussion
The study found that mice producing anti-CFH antibodies exhibited significantly improved outcomes. These mice had lower levels of urinary protein and serum creatinine compared to the standard pristane-induced lupus group.
Histological Amelioration
Histological examination revealed that the presence of anti-CFH antibodies greatly reduced renal damage. Glomerular inflammation and immune complex deposition were markedly lower in the protected group.
Mechanism of Protection
Unlike pathogenic antibodies that inhibit their targets, these anti-CFH antibodies (primarily IgG1) functioned as enhancers. In vitro assays demonstrated that these antibodies increased the binding affinity between CFH and C3b, thereby making the complement "brake" more effective. This enhancement led to a systemic reduction in lupus markers, including anti-dsDNA antibodies and IL-6.
Conclusion
This research highlights a novel paradigm where autoantibodies can play a protective role in autoimmune disease. By enhancing the natural regulatory function of CFH, these antibodies mitigate the runaway inflammation characteristic of lupus nephritis. While direct induction of autoantibodies is not a feasible human therapy, these findings suggest that developing monoclonal antibodies or small molecules that mimic this enhancing effect could provide a new therapeutic avenue for LN patients.
Summary updated